Dupixent, Consumer Healthcare Lifts Sanofi's Q1 Earnings, Backs FY22 Guidance

  • Sanofi SA SNY posted a net profit of €2 billion for Q1 FY22, up from €1.57 billion a year ago. Sales reached €9.67 billion, up from €8.59 billion in Q1 FY21.
  • Eczema drug, Dupixent, and consumer healthcare drove the growth.
  • Dupixent alone grew by 45.7% to €1.6 billion, driving Sanofi's specialty care business sales.
  • Sanofi said that net income clocked in at €2.42 billion, from €2.02 billion a year ago.
  • Also See: EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine.
  • First-quarter vaccine sales increased 6.8% to €1.02 billion, driven by double-digit growth of Polio/Pertussis/Hib vaccine sales and partial recovery of travel vaccines.
  • Consumer healthcare sales increased 17.0% to €1.33 billion, mainly driven by the strong demand for Cough & Cold products and the performance of Pain Care and Digestive Wellness categories.
  • EPS was €1.94, up 20.5% from the prior-year level.
  • Sanofi expects 2022 business EPS to grow low-double-digit at constant exchange rates, with a 4% - 5% positive currency impact.
  • Price Action: SNY shares are down 0.75% at $53.93 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!